Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

230 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Impact of baseline severity of aortic valve stenosis on effect of intensive lipid lowering therapy (from the SEAS study).
Gerdts E, Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gohlke-Bärwolf C, Holme I, Kesäniemi YA, Malbecq W, Nienaber C, Ray S, Skjærpe T, Wachtell K, Willenheimer R. Gerdts E, et al. Among authors: pedersen tr. Am J Cardiol. 2010 Dec 1;106(11):1634-9. doi: 10.1016/j.amjcard.2010.07.042. Epub 2010 Oct 14. Am J Cardiol. 2010. PMID: 21094366 Clinical Trial.
Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial.
Murphy SA, Pedersen TR, Gaciong ZA, Ceska R, Ezhov MV, Connolly DL, Jukema JW, Toth K, Tikkanen MJ, Im K, Wiviott SD, Kurtz CE, Honarpour N, Giugliano RP, Keech AC, Sever PS, Sabatine MS. Murphy SA, et al. Among authors: pedersen tr. JAMA Cardiol. 2019 Jul 1;4(7):613-619. doi: 10.1001/jamacardio.2019.0886. JAMA Cardiol. 2019. PMID: 31116355 Free PMC article. Clinical Trial.
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial.
Sabatine MS, Leiter LA, Wiviott SD, Giugliano RP, Deedwania P, De Ferrari GM, Murphy SA, Kuder JF, Gouni-Berthold I, Lewis BS, Handelsman Y, Pineda AL, Honarpour N, Keech AC, Sever PS, Pedersen TR. Sabatine MS, et al. Among authors: pedersen tr. Lancet Diabetes Endocrinol. 2017 Dec;5(12):941-950. doi: 10.1016/S2213-8587(17)30313-3. Epub 2017 Sep 15. Lancet Diabetes Endocrinol. 2017. PMID: 28927706 Clinical Trial.
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.
Giugliano RP, Pedersen TR, Park JG, De Ferrari GM, Gaciong ZA, Ceska R, Toth K, Gouni-Berthold I, Lopez-Miranda J, Schiele F, Mach F, Ott BR, Kanevsky E, Pineda AL, Somaratne R, Wasserman SM, Keech AC, Sever PS, Sabatine MS; FOURIER Investigators. Giugliano RP, et al. Among authors: pedersen tr. Lancet. 2017 Oct 28;390(10106):1962-1971. doi: 10.1016/S0140-6736(17)32290-0. Epub 2017 Aug 28. Lancet. 2017. PMID: 28859947 Clinical Trial.
Evolocumab in Patients with Cardiovascular Disease.
Sabatine MS, Giugliano RP, Pedersen TR. Sabatine MS, et al. Among authors: pedersen tr. N Engl J Med. 2017 Aug 24;377(8):787-8. doi: 10.1056/NEJMc1708587. N Engl J Med. 2017. PMID: 28834471 No abstract available.
230 results